#PODCAST: 2900 people are expected to partake in the second COVID-19 vaccine trial in South Africa

By Newsbreak Producer Tashlan Naidoo - Wits University in Johannesburg, will begin screening participants for a second coronavirus vaccine trial today. The aim of the trial is to evaluate a particle in the vaccine that protects against the corona virus in adults aged between 18-and 64. The nanoparticle S-protein, known as NVX-CoV2373, is produced by biotech company, Novavax, in the United States. Wits Professor of Vaccinology, Shabir Madhi is leading the trial and explains how it will be carried out...